CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership2,362 shares
Latest Disclosed Value $ 114,887
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 4.91% decrease in ownership of CRSP / CRISPR Therapeutics AG

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 2,362 shares of CRISPR Therapeutics AG (US:CRSP) valued at $114,888 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 2,484 shares of CRISPR Therapeutics AG. This represents a change in shares of -4.91% during the quarter. The current value of the position is $134,516 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP CRISPR Therapeutics EC CH0334081137 2,362 -122 -4.91 115 35.71 1.2768
2025-05-29 2025-03-31 NP CRISPR Therapeutics EC CH0334081137 2,484 158 6.79 85 -7.69 0.8980
2025-03-03 2024-12-31 NP CRISPR Therapeutics EC CH0334081137 2,326 -548 -19.07 92 -32.59 0.9178
2024-11-29 2024-09-30 NP CRISPR Therapeutics EC CH0334081137 2,874 758 35.82 135 18.42 1.2229
2024-08-29 2024-06-30 NP CRISPR Therapeutics EC CH0334081137 2,116 -87 -3.95 114 -24.00 1.0419
2024-05-30 2024-03-31 NP CRISPR Therapeutics EC CH0334081137 2,203 170 8.36 150 18.11 1.2734
2024-02-29 2023-12-31 NP CRISPR Therapeutics EC CH0334081137 2,033 -990 -32.75 127 -7.30 1.0431
2023-11-29 2023-09-30 NP CRISPR Therapeutics EC CH0334081137 3,023 494 19.53 137 -2.84 1.1880
2023-08-28 2023-06-30 NP CRISPR Therapeutics EC CH0334081137 2,529 -855 -25.27 142 -7.84 1.1204
2023-05-30 2023-03-31 NP CRISPR Therapeutics EC CH0334081137 3,384 -1,006 -22.92 153 -14.04 1.1593
2023-02-28 2022-12-31 NP CRISPR Therapeutics EC CH0334081137 4,390 1,363 45.03 178 -9.64 1.0792
2022-11-29 2022-09-30 NP CRISPR Therapeutics EC CH0334081137 3,027 784 34.95 198 44.85 1.3805
2022-08-29 2022-06-30 NP CRISPR Therapeutics EC CH0334081137 2,243 -168 -6.97 136 -9.93 0.9351
2022-05-26 2022-03-31 NP CRISPR Therapeutics EC CH0334081137 2,411 -1,512 -38.54 151 -49.16 0.8943
2022-02-28 2021-12-31 NP CRISPR Therapeutics EC CH0334081137 3,923 1,464 59.54 297 8.00 1.3137
2021-11-29 2021-09-30 NP CRISPR Therapeutics EC CH0334081137 2,459 -466 -15.93 275 -41.86 1.1570
2021-08-27 2021-06-30 NP CRISPR Therapeutics EC CH0334081137 2,925 -42 -1.42 474 31.02 1.9833
2021-05-27 2021-03-31 NP CRISPR Therapeutics EC CH0334081137 2,967 876 41.89 362 12.81 1.6268
2021-03-01 2020-12-31 NP CRISPR Therapeutics EC CH0334081137 2,091 2,091 320 1.3038
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.